Werewolf Therapeutics, Inc. (NASDAQ:HOWL) Sees Large Growth in Short Interest

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) saw a significant increase in short interest in January. As of January 15th, there was short interest totalling 1,720,000 shares, an increase of 13.2% from the December 31st total of 1,520,000 shares. Approximately 5.2% of the shares of the stock are sold short. Based on an average daily volume of 773,000 shares, the days-to-cover ratio is currently 2.2 days.

Werewolf Therapeutics Trading Up 0.4 %

HOWL stock traded up $0.01 during mid-day trading on Monday, reaching $1.35. 164,512 shares of the stock traded hands, compared to its average volume of 271,389. The business has a 50-day moving average price of $1.58 and a two-hundred day moving average price of $2.01. The company has a debt-to-equity ratio of 0.29, a quick ratio of 10.10 and a current ratio of 10.10. The stock has a market capitalization of $59.93 million, a PE ratio of -0.88 and a beta of 0.36. Werewolf Therapeutics has a one year low of $1.26 and a one year high of $8.19.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. PFM Health Sciences LP grew its holdings in shares of Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock worth $7,205,000 after purchasing an additional 157,673 shares during the last quarter. Millennium Management LLC grew its holdings in shares of Werewolf Therapeutics by 96.4% in the second quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock worth $2,709,000 after purchasing an additional 544,881 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Werewolf Therapeutics by 6.3% in the third quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock worth $1,454,000 after purchasing an additional 40,692 shares during the last quarter. State Street Corp grew its holdings in shares of Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after purchasing an additional 52,528 shares during the last quarter. Finally, Renaissance Technologies LLC grew its holdings in shares of Werewolf Therapeutics by 103.1% in the second quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock worth $417,000 after purchasing an additional 86,800 shares during the last quarter. 64.84% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on HOWL shares. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Werewolf Therapeutics in a research report on Tuesday, November 19th. JMP Securities cut their price objective on shares of Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating on the stock in a research report on Tuesday, January 14th.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.